Browsing University of Galway Support Services by Author "Quax, W. J."
Now showing items 1-2 of 2
-
Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the dr5 receptor
van der Sloot, A. M.; Tur, V.; Szegezdi, E.; Mullally, M. M.; Cool, R. H.; Samali, A.; Serrano, L.; Quax, W. J. (Proceedings of the National Academy of Sciences, 2006-05-26)Tumor necrosis factor-related apoptosis-inclucing ligand (TRAIL) is a potential anticancer drug that selectively induces apoptosis in a variety of cancer cells by interacting with death receptors DR4 and DR5. TRAIL can ... -
Enhanced antitumor efficacy of a dr5-specific trail variant over recombinant human trail in a bioluminescent ovarian cancer xenograft model
Duiker, E. W.; de Vries, E. G.E.; Mahalingam, D.; Meersma, G. J.; Boersma-van Ek, W.; Hollema, H.; Lub-de Hooge, M. N.; van Dam, G. M.; Cool, R. H.; Quax, W. J.; Samali, A.; van der Zee, A. G.J.; de Jong, S. (American Association for Cancer Research (AACR), 2009-03-10)Purpose: Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL) is clinically evaluated as novel anticancer drug. rhTRAIL-DR5, a rhTRAIL variant that specifically binds to DR5 receptor, has ...